Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2014-01-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-014-2836-7PMID 24469642PMCID PMC4133778
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERBB2 inhibition and heart failure.

  2013cited by this paper
• Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

  2013cited by this paper
• 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

  2013cited by this paper
• years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial

  2013cited by this paper
• Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

  2012cited by this paper
• Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

  2012cited by this paper
• Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.

  2012cited by this paper
• Cardiac Side Effects of Anticancer Treatments: New Mechanistic Insights

  2012cited by this paper
• ERBB2 inhibition and heart failure.

  2012cited by this paper
• Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

  2012cited by this paper
• Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.

  2011cited by this paper
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

  2011cited by this paper
• Cardiac toxicity from systemic cancer therapy: a comprehensive review.

  2010cited by this paper
• Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.

  2008cited by this paper
• Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

  2007cited by this paper
• Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.

  2006cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors

  2005cited by this paper
• Trastuzumab‐associated cardiotoxicity

  2002cited by this paper
• Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population

  2002cited by this paper
• Development of a comorbidity index using physician claims data.

  2000cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• Estimating Causal Effects from Large Data Sets Using Propensity Scores

  1997cited by this paper

• Examining factors associated with experiencing cardiac arrhythmias in Black and White breast cancer survivors who received anthracyclines or trastuzumab

  2025cites this paper
• Cardiotoxicity in Elderly Breast Cancer Patients

  2025influential citation
• Application of 2‐Dimensional Speckle Tracking Technology for Trastuzumab‐Induced Cardiotoxicity in a New Mouse Model

  2025cites this paper
• Epidemiology, Pathophysiology, and Management of Cancer-Associated Ischemic Stroke

  2024cites this paper
• Predictive Modeling of Long-Term Survivors with Stage IV Breast Cancer Using the SEER-Medicare Dataset

  2024cites this paper
• Characteristics and research status among clinical trials in cardio‐oncology by bibliometric and visualized analysis

  2023cites this paper
• Cardiotoxicity among socioeconomically marginalized breast cancer patients

  2022cites this paper
• Treatment results and patient characeristics for breast cancer patients older than 70 Years

  2022cites this paper
• Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction

  2022cites this paper
• Racial disparities in treatment-related cardiovascular toxicities amongst women with breast cancer: a scoping review

  2022cites this paper
• Social, political, and economic determinants of access to biologics: A scoping review of structural determinants in the clinical disparities literature.

  2022cites this paper
• Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?

  2020cites this paper
• Practical and cost-effective model to build and sustain a cardio-oncology program

  2020cites this paper
• NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients

  2020cites this paper
• Left Ventricular Dysfunction in Breast Cancer Patients Receiving Trastuzumab: An Observational Study in a Cohort of Iraqi Breast Cancer Patients

  2019cites this paper
• Adjuvant Systemic Therapy

  2019cites this paper
• Management of Cardiovascular Disease in Women With Breast Cancer

  2019cites this paper
• Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker.

  2018cites this paper
• Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies.

  2018cites this paper
• Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

  2018cites this paper
• Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016).

  2018cites this paper
• Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives

  2018cites this paper
• SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.

  2017cites this paper
• Initiation of Trastuzumab by Women Younger Than 64 Years for Adjuvant Treatment of Stage I-III Breast Cancer.

  2017cites this paper
• Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology

  2017cites this paper
• Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort

  2017cites this paper
• Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

  2017cites this paper
• Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or &bgr;-blockers in Older Adults With Breast Cancer

  2017cites this paper
• Systemic Treatment of Cancer in the Older-Aged Person

  2016cites this paper
• Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.

  2016cites this paper
• Cardiomyopathy Associated With Targeted Therapy for Breast Cancer

  2016cites this paper
• Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer

  2016cites this paper
• Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.

  2016cites this paper
• Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?

  2015cites this paper
• Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?

  2015cites this paper
• Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level.

  2015cites this paper
• Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines.

  2015cites this paper
• Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data

  2015cites this paper
• Optimal management of breast cancer in the elderly patient: current perspectives

  2015cites this paper
• Targeted therapy in older patients with solid tumors.

  2014cites this paper
• Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival

  2014cites this paper